Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
- Previous Close
1,466.05 - Open
1,468.95 - Bid --
- Ask --
- Day's Range
1,455.95 - 1,479.10 - 52 Week Range
960.75 - 1,638.85 - Volume
2,616,311 - Avg. Volume
2,806,171 - Market Cap (intraday)
3.515T - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
36.73 - EPS (TTM)
39.88 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield 12.50 (0.85%)
- Ex-Dividend Date Feb 9, 2024
- 1y Target Est
829.22
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and anti retro viral medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.
www.sunpharma.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUNPHARMA.NS
Performance Overview: SUNPHARMA.NS
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUNPHARMA.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUNPHARMA.NS
Valuation Measures
Market Cap
3.52T
Enterprise Value
3.35T
Trailing P/E
36.74
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.37
Price/Book (mrq)
5.52
Enterprise Value/Revenue
7.01
Enterprise Value/EBITDA
24.13
Financial Highlights
Profitability and Income Statement
Profit Margin
19.75%
Return on Assets (ttm)
7.84%
Return on Equity (ttm)
15.20%
Revenue (ttm)
484.97B
Net Income Avi to Common (ttm)
95.76B
Diluted EPS (ttm)
39.88
Balance Sheet and Cash Flow
Total Cash (mrq)
191.05B
Total Debt/Equity (mrq)
4.88%
Levered Free Cash Flow (ttm)
75.42B